Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antidotes

Antidotes

Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Pharmaceutical Poisoning: Treatment Strategies

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Current opinion: the OCEANIC trial journey: from failure to breakthrough?

European heart journal. Cardiovascular pharmacotherapy·2026

Same author

Obesity and Pharmacokinetic Variability: Implications for Cardiovascular Therapeutics.

European cardiology·2026

Same author

Innovation and constraints in cardiovascular pharmacotherapy.

European heart journal. Cardiovascular pharmacotherapy·2026

Same author

Thrombophilia Screening in Young Patients With Cryptogenic Ischemic Stroke.

Stroke·2026

Same author

ADAPT AF-DES and the Limits of Non-inferiority in Long-term Antithrombotic Therapy.

European cardiology·2026

Same author

Glycoprotein IIb/IIIa Blockade: Ready to CELEBRATE a New Dawn?

European cardiology·2026

Same journal

Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609.

The New England journal of medicine·2026

Same journal

Opportunities to Combat the Chronic Pain-Opioid Use Disorder Syndemic.

The New England journal of medicine·2026

Same journal

The Invisible Load of Cognitive Symptoms.

The New England journal of medicine·2026

Same journal

Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia.

The New England journal of medicine·2026

Same journal

Cat Scratch Disease.

The New England journal of medicine·2026

Same journal

Declarations of Independence - Physicians and the U.S. Body Politic, 1776-2026.

The New England journal of medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Antidotes for Anticoagulation Reversal.

Bianca Rocca¹, Hugo Ten Cate^2,3

¹Department of Medicine and Surgery, LUM University, Bari, Italy.

The New England Journal of Medicine

|June 10, 2026

Summary

This summary is machine-generated.

Effective reversal of anticoagulants is crucial due to increased bleeding events. Strategies must consider drug properties, evidence, and patient factors for optimal hemostatic care.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Experiment Videos

Last Updated: Jun 12, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Area of Science:

Pharmacology
Hematology
Clinical Medicine

Background:

Anticoagulant use is rising globally, leading to more major bleeding events.
Effective pharmacologic reversal strategies are essential for patient safety.
Current reversal options vary in efficacy and availability for different anticoagulants.

Purpose of the Study:

To review current anticoagulant reversal strategies.
To highlight challenges and gaps in evidence for reversal agents.
To discuss emerging agents and future directions in hemostatic care.

Main Methods:

Literature review of pharmacodynamic and pharmacokinetic properties of anticoagulants and antidotes.
Analysis of regulatory indications, evidence quality, and patient-specific factors.
Evaluation of existing reversal agents (e.g., protamine sulfate, PCCs, idarucizumab, andexanet alfa) and emerging therapies.

Main Results:

Protamine sulfate neutralizes unfractionated heparin; no specific antidotes for LMWHs or fondaparinux.
Four-factor prothrombin complex concentrates (PCCs) effectively reverse vitamin K antagonists.
Idarucizumab reverses dabigatran, with potential for rebound; andexanet alfa targets Factor Xa inhibitors but faces uncertainties, leading to off-label PCC use.

Conclusions:

Significant challenges remain in anticoagulant reversal, including dosing, monitoring, and perioperative management.
Development of high-quality evidence is critical for advancing patient-centered anticoagulant and hemostatic care.
Emerging agents offer potential for broader targets and improved safety profiles.